Skip to main content
. Author manuscript; available in PMC: 2017 Feb 1.
Published in final edited form as: Am J Transplant. 2015 Nov 9;16(2):672–678. doi: 10.1111/ajt.13483

Figure 4. Effects of anti-CD20 mAbs on memory T cell reactivation and allograft rejection in allosensitized mice.

Figure 4

(A) OT1 mice received two skin grafts from Act mOVA donors at day 0 and day 100. Five days before the second graft, some recipients were treated with anti-CD20 mAbs. (B) This panel shows the frequencies of alloreactive memory T cells producing γ-interferon (γ-IFN) in untreated (gray bars) or mice treated with anti-CD20 mAbs (black bars) measured 40 days after the second graft via in vitro stimulation with intact donor OVA transgenic antigen-presenting cells (APCs) (endogenous processing) or recipient B6 APCs + OVA-transgenic donor sonicates (exogenous processing). Controls included T cells stimulated with syngeneic APCs, syngeneic sonicates, or medium. The results are expressed as numbers of γ-IFN spots per million T cells and represent three mice tested individually±standard deviation. Panel (C) shows the percentages of first (dotted lines) and second graft (solid lines) survival overtime for untreated OT1 control mice (gray lines) and anti-CD20 mAb-treated mice (black bars).